Q1 EPS Estimates for Stoke Therapeutics Increased by Wedbush

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at Wedbush upped their Q1 2025 earnings per share estimates for Stoke Therapeutics in a report released on Tuesday, March 18th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.57) for the quarter, up from their prior estimate of ($0.58). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.37) EPS, FY2026 earnings at ($3.02) EPS, FY2027 earnings at ($3.13) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at ($2.01) EPS.

A number of other research analysts have also recently issued reports on STOK. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. Chardan Capital reiterated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics has a consensus rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $8.15 on Friday. Stoke Therapeutics has a 52 week low of $5.93 and a 52 week high of $17.58. The stock’s fifty day moving average is $9.47 and its 200 day moving average is $11.45. The stock has a market capitalization of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its stake in Stoke Therapeutics by 145.3% in the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after buying an additional 47,239 shares during the period. Geode Capital Management LLC lifted its stake in Stoke Therapeutics by 9.7% in the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after buying an additional 76,661 shares during the period. State Street Corp lifted its stake in Stoke Therapeutics by 8.6% in the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after buying an additional 137,145 shares during the period. RTW Investments LP lifted its stake in Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after buying an additional 427,447 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in Stoke Therapeutics by 1,589.7% in the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after buying an additional 71,647 shares during the period.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,532 shares of company stock worth $143,332. Insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.